Literature DB >> 1175419

Acute pulmonary hypersensitivity to carbamazepine.

S A Cullinan, G C Bower.   

Abstract

Acute pulmonary hypersensitivity to carbamazepine (Tegretol) is reported, manifested by diffuse pulmonary infiltrates, skin rash, and eosinophilia. The reaction cleared on cessation of the drug. A lymphocyte transformation test was reactive to carbamazepine.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1175419     DOI： 10.1378/chest.68.4.580

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  8 in total

1.  Extensive carbamazepine eruption with eosinophilia and pulmonary infiltrate.

Authors:  N H Cox; S R Johnston; J Marks; D Bates
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

2.  Cross Hypersensitivity Syndrome between Phenytoin and Carbamazepine.

Authors:  Nerea Moyano Sierra; Benito García; Javier Marco; Susana Plaza; Francisco Hidalgo; Teresa Bermejo
Journal:  Pharm World Sci       Date:  2005-06

3.  Pulmonary eosinophilia and asthma associated with carbamazepine.

Authors:  T Lee; G M Cochrane; P Amlot
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-07

4.  Glandular fever-like syndrome, pulmonary eosinophilia and asthma associated with carbamazepine.

Authors:  I J Lewis; L Rosenbloom
Journal:  Postgrad Med J       Date:  1982-02       Impact factor: 2.401

Review 5.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

6.  [Spectrum of hypereosinophilia syndrome based on 2 clinical case reports].

Authors:  H Nolte; U Helmchen
Journal:  Med Klin (Munich)       Date:  1998-07-15

7.  Pulmonary eosinophilia associated with carbamazepine.

Authors:  J Tolmie; C R Steer; A T Edmunds
Journal:  Arch Dis Child       Date:  1983-10       Impact factor: 3.791

Review 8.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.